The main contributing factor to this market is the growing incidence of bleeding disorders and an upsurge in the number of approvals associated to fibrinogen concentrate.

However, certain negative reactions including arterial thrombosis, chills, dyspnea, nausea, vomiting, and pulmonary embolism confine the growth.